Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA (NWRN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.

The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis, schizoprenia, and neuropathic pain.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20152016Delta
CHF (in Million)%CHF (in Million)%
Pharmaceutical Drugs2.43100%5.16100% +112.52%
Sales per Regions
20152016Delta
CHF (in Million)%CHF (in Million)%
Global2.43100%5.16100% +112.52%
Managers
NameAgeSinceTitle
Stefan Weber532005Chief Executive Officer, Director & IR Contact
Ulrich Köstlin, PhD662013Non-Executive Chairman
Roberto Galli-2002Vice President-Finance
Ravi Anand, MD612005Chief Medical Officer
Patrick J. Langlois, PhD732008Independent Non-Executive Director
Robert Leslie Holland MD, PhD632013Independent Non-Executive Director
Bo Jesper Hansen MD, PhD602013Independent Non-Executive Director
Joseph Donald deBethizy, PhD672014Independent Non-Executive Director
Luca Benatti, PhD572014Independent Non-Executive Director
Marco Caremi612002Executive Vice President-Business Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 17,837,345 14,177,422 79.5% 0 0.0% 79.5%
Shareholders
NameEquities%
Investor AB 1,670,317 9.36%
Aviva Plc 1,258,251 7.05%
Gefim SpA 785,448 4.40%
JPMorgan Asset Management (UK) Ltd. 311,633 1.75%
UBS AG (Investment Management) 305,049 1.71%
Polar Capital LLP 198,573 1.11%
EFG Asset Management (UK) Ltd. 170,000 0.95%
Union Investment Privatfonds GmbH 149,140 0.84%
Kairos Partners SGR SpA 134,859 0.76%
Zürcher Kantonalbank (Investment Management) 131,288 0.74%
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA-13.79%194
GILEAD SCIENCES10.83%105 375
VERTEX PHARMACEUTICALS5.16%39 931
REGENERON PHARMACEUTICALS-16.00%34 113
BIOVERATIV INC93.43%11 243
GENMAB16.62%10 343
BLUEBIRD BIO INC12.97%10 168
JUNO THERAPEUTICS INC89.37%9 892
EXELIXIS, INC.-4.28%8 577
BEIGENE LTD (ADR)59.54%7 915
NEUROCRINE BIOSCIENCES, INC.10.09%7 508
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.1.14%6 161
BIOCON LTD15.97%5 360
PEPTIDREAM INC23.16%5 295
AGIOS PHARMACEUTICALS INC43.10%4 511
AVEXIS INC8.01%4 189
SAREPTA THERAPEUTICS INC13.25%4 086
HUALAN BIOLOGICAL ENGINEERING INC--.--%3 801
ARRAY BIOPHARMA INC39.77%3 480
TESARO INC-26.52%3 372
IDORSIA LTD3.65%3 332
Connections : Newron Pharmaceuticals SpA
PJL Consulting
DFC Langlois
Wellington Partners GmbH
Oxford Gene Technology IP Ltd.
Early Clinical Development Consulting Ltd.
Constantia Flexibles Group GmbH
LABORIE Medical Technologies, Inc.
White City Consulting ApS
Innoventa Medica ApS
Universitätsklinikum Würzburg
Proterris, Inc.
European School of Management & Technology GmbH
EryDel SpA
Assobiotec
NOXXON Pharma AG
Constantia Flexibles AG
Italian Angels For Biotech
MipSalus ApS
Azanta A/S
The European Association for Bioindustries
© 2018 People , Fundamentals and Ownership